Research Overview
· Last Reviewed May 3, 2026· PSI Editorial Board· IndependentCan Peptides Improve My Cognition?
The honest map across 8 cognitive scenarios: what's been studied, what's reached human trials, and where validated treatments still rule.
WHAT'S YOUR PRIMARY INTEREST?
Cognitive Domain
Animal Studies
Human Trials
Post-stroke cognitive recovery
ischemic stroke, motor + cognitive
Traumatic brain injury
post-TBI cognitive sequelae
Alzheimer's disease and vascular dementia
neurodegeneration
Generalized anxiety disorder
anxiety with cognitive impact
Working memory and attention
focus, executive function
Dendritic spine density and synaptic plasticity
structural cognitive substrate
Cognitive resilience under stress
stress-induced cognitive decline
NGF / BDNF mimicry for neurodegeneration
preclinical Alzheimer's research
How counts are scaled → · Tap any row to see the studies →
Quick Answer
Cognitive-enhancement peptides span the full evidence spectrum, from internationally-approved clinical agents through Russian clinical use to preclinical-only research compounds. None has US FDA approval for any cognitive indication. The validated treatments for cognitive disorders are cholinesterase inhibitors, memantine, anti-amyloid antibodies for Alzheimer's, and stimulants for ADHD. Foundational lifestyle interventions are sleep, exercise, Mediterranean dietary patterns, and social engagement.
Cerebrolysin has the deepest clinical evidence base on this page. The compound is a complex of low-molecular-weight peptides and amino acids derived from purified porcine brain proteins. EVER Neuro Pharma manufactures it in Austria. The drug is approved in over 50 countries (not the US) for ischemic stroke, traumatic brain injury, and vascular dementia. Adjuvant Alzheimer's disease use is approved in some jurisdictions. Multiple Phase 3 trials and meta-analyses support efficacy in early post-stroke recovery, including the CARS (Cerebrolysin and Recovery After Stroke) trial program. Effect sizes are modest but reproducible across study sites. The mechanism is neurotrophic mimicry — the peptide complex mimics endogenous neurotrophin signaling (BDNF, NGF, GDNF, CNTF) on damaged neurons.
Semax is a synthetic heptapeptide based on the 4-7 fragment of adrenocorticotropic hormone (ACTH) extended with a Pro-Gly-Pro tripeptide. The Myasoedov laboratory at the Russian Academy of Sciences developed the compound. It is registered in Russia for ischemic stroke recovery and cognitive disorders. The mechanism includes BDNF and NGF expression upregulation in cortex and hippocampus. Russian clinical trials report cognitive performance and stroke recovery benefits. Western controlled trials are absent.
Selank is a synthetic heptapeptide based on the immunomodulator tuftsin extended with the same Pro-Gly-Pro tripeptide as Semax. It is registered in Russia for generalized anxiety disorder. Mechanisms include anxiolytic activity through GABA and serotonin pathways plus BDNF modulation. Russian clinical literature reports anxiolytic effects comparable to benzodiazepines without sedation or dependence. Western controlled trials are absent.
Dihexa is a synthetic hexapeptide derivative of angiotensin IV. Joseph Harding and the Wright laboratory at Washington State University developed it. The mechanism is HGF (hepatocyte growth factor) mimicry — the peptide augments HGF binding to its c-Met receptor, triggering dendritic spinogenesis and synaptic remodeling. Animal studies report dramatic cognitive enhancement in scopolamine-induced and aged-rat models. Zero published controlled human trials.
PE-22-28 is a peptide derived from the propeptide of sortilin (Spadin). The Heurteaux and Mazella laboratory at CNRS France developed it. The mechanism is TREK-1 potassium channel inhibition, conferring antidepressant activity in animal models with faster onset than SSRIs and cognitive resilience effects under stress. Zero published human trials.
P21 (also called acidic-Y17) is a synthetic 11-amino-acid peptide developed by the Iqbal laboratory at the New York State Institute for Basic Research. The mechanism is NGF mimicry through partial agonism at TrkA receptors plus BDNF modulation. Animal Alzheimer's-model studies report reduced amyloid pathology, restored synaptic markers, and improved cognitive performance. Zero published human trials.
The honest framing: peptide research for cognition is one of the strongest mechanism categories in the broader peptide field. Cerebrolysin has translated into a real clinical drug abroad. Semax and Selank have decades of Russian clinical use. Dihexa, PE-22-28, and P21 have compelling preclinical biology. None has US FDA approval for cognitive enhancement. For diagnosed cognitive disorders, validated treatments and lifestyle interventions remain the primary evidence base. For specific cognitive contexts, see Peptides for Longevity (mitochondrial-derived peptides for cognitive aging) and Peptides for Sleep (sleep-cognition link).
Peptides vs cholinesterase inhibitors and memantine for Alzheimer's and dementia
Where research peptides stand against the validated dementia-care evidence base
Most adults researching peptides for cognition have or know someone with cognitive decline, mild cognitive impairment, or diagnosed Alzheimer's disease and vascular dementia. The honest comparison: cholinesterase inhibitors, memantine, and now anti-amyloid monoclonal antibodies are FDA-approved drugs with substantial Phase 3 trial evidence. Peptides at this stage are research-grade biology with limited or no controlled human dementia trial evidence in the United States.
Cholinesterase inhibitors are the foundation of mild-to-moderate Alzheimer's care. Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne) are FDA-approved with multiple Phase 3 trials supporting cognitive and functional benefit. Effect sizes are modest but reproducible. Memantine (Namenda), an NMDA receptor antagonist, is FDA-approved for moderate-to-severe Alzheimer's disease, often used in combination with cholinesterase inhibitors. The cholinesterase plus memantine combination protocol is the established standard for moderate-stage disease.
Anti-amyloid monoclonal antibodies have transformed the Alzheimer's landscape. Lecanemab (Leqembi) received FDA accelerated approval in 2023 and traditional approval based on Phase 3 CLARITY-AD trial data showing slowed cognitive decline. Donanemab (Kisunla) followed with FDA approval in 2024 based on TRAILBLAZER-ALZ 2 trial data. These agents target amyloid plaque clearance and represent the first disease-modifying therapies in Alzheimer's disease. Effect sizes are modest but represent genuine disease modification rather than purely symptomatic treatment.
Cerebrolysin has international approval in over 50 countries for adjunctive use in Alzheimer's disease and stroke recovery. The compound's neurotrophic mimicry mechanism is mechanistically distinct from cholinesterase inhibition or amyloid clearance. Some Phase 3 RCTs report cognitive benefits when added to donepezil. Cerebrolysin is not US FDA-approved and is essentially absent from US Alzheimer's clinical practice. Other cognitive-enhancement peptides (Semax, Selank, Dihexa, PE-22-28, P21) have either Russian clinical use or preclinical-only evidence in dementia indications.
PSI's reading: for diagnosed Alzheimer's disease and dementia, validated treatments are the dominant evidence base. Patients should work with neurology and geriatric medicine on cholinesterase inhibitors, memantine, and where appropriate the anti-amyloid antibodies. Cerebrolysin may be discussed where international access is available. Other peptides remain research-grade. Substituting peptides for validated dementia treatment risks accelerated decline and is not evidence-supported.
Peptides vs ADHD stimulants and lifestyle interventions for cognitive performance
Healthy-adult cognitive enhancement and the validated approaches
Many adults researching cognitive-enhancement peptides are not addressing diagnosed disease but instead exploring augmentation of normal cognitive performance. The validated comparison set for healthy-adult cognitive enhancement is different from the dementia comparison. It centers on FDA-approved stimulants for diagnosed ADHD, lifestyle interventions with the deepest cohort evidence, and validated nutraceuticals.
FDA-approved ADHD stimulants include methylphenidate (Ritalin, Concerta), amphetamine salts (Adderall, Vyvanse), and non-stimulant atomoxetine (Strattera). These agents have decades of Phase 3 trial evidence in diagnosed ADHD with established benefit on attention, executive function, and academic or workplace performance. Off-label use for cognitive enhancement in non-ADHD adults is widespread but raises clinical, ethical, and legal questions. Side-effect profiles include cardiovascular effects, sleep disruption, appetite suppression, and dependence liability that limit long-term use in healthy adults.
Lifestyle interventions carry the deepest evidence for sustained cognitive performance across the adult lifespan. Sleep duration of 7 to 9 hours nightly correlates with preserved cognitive performance and reduced dementia risk. Aerobic exercise of 150 minutes weekly improves cognitive performance, hippocampal volume, and reduces dementia incidence in cohort studies. Resistance training adds independent cognitive benefits. Mediterranean dietary patterns reduce cognitive decline rates in adults including the PREDIMED-Plus trial cohorts. Social engagement and continued learning carry effect sizes comparable to pharmacological intervention in observational studies.
Validated nutraceuticals with genuine cognitive-enhancement evidence in healthy adults include caffeine (acute focus and reaction time, effect well-characterized in dozens of controlled trials), L-theanine (combined with caffeine for reduced stimulation jitter), creatine monohydrate (cognitive performance under sleep deprivation, growing evidence base), and omega-3 fatty acids (modest effect on age-related cognitive decline in cohort studies).
Cognitive-enhancement peptides on this page have either Russian clinical use (Semax, Selank for cognitive performance under stress) or preclinical-only evidence (Dihexa, PE-22-28, P21 in healthy-adult cognitive enhancement). Cerebrolysin is approved abroad for stroke and dementia, not for healthy-adult cognitive enhancement. PSI's reading: for healthy adults seeking cognitive enhancement, validated lifestyle interventions and well-characterized nutraceuticals are the dominant evidence base. Peptides may have a research-grade exploratory role under physician supervision. They are not substitutes for sleep, exercise, dietary patterns, or social engagement.
Peptides vs anti-anxiety medications for anxiety-related cognitive impairment
Selank's positioning against benzodiazepines and SSRIs
Anxiety with secondary cognitive impact is a major reason adults research cognitive-enhancement peptides. Chronic anxiety impairs working memory, attention, decision-making, and consolidation of new learning. Validated treatments for anxiety with cognitive impact include SSRIs (sertraline, escitalopram, paroxetine), SNRIs (venlafaxine, duloxetine), buspirone, benzodiazepines for short-term use, and cognitive-behavioral therapy.
SSRIs are the long-term first-line standard. Multiple Phase 3 trials support SSRI efficacy in generalized anxiety disorder, social anxiety disorder, panic disorder, and post-traumatic stress disorder. Effect sizes are moderate but reproducible across trials. The cognitive impact of effective SSRI treatment is generally improvement, as anxiety reduction restores cognitive bandwidth. Onset typically takes 2 to 6 weeks. SSRIs are available, well-characterized, and broadly accessible.
Benzodiazepines (diazepam, alprazolam, lorazepam, clonazepam) provide rapid anxiolytic effect but carry sedation, cognitive impairment, and dependence liability that limit long-term use. The cognitive impact of benzodiazepines is well-characterized: short-term anxiety reduction at the cost of attention, working memory, and motor performance. Long-term benzodiazepine use is associated with persistent cognitive deficits in some cohorts. Discontinuation can be challenging due to withdrawal and rebound anxiety. Benzodiazepines are appropriate for short-term acute use only, not for long-term anxiety management.
Selank, the Russian-approved peptide for generalized anxiety disorder, is positioned in Russian clinical literature as anxiolytic with efficacy comparable to benzodiazepines without sedation, cognitive impairment, or dependence liability. The mechanism through GABA, serotonin, and BDNF pathways is mechanistically distinct from benzodiazepine GABA-A potentiation. Russian clinical trials report concurrent anxiety reduction and cognitive performance improvement in patients with generalized anxiety disorder. Western controlled trials are absent. The Russian evidence base is real but inaccessible to most Western evidence synthesis.
PSI's reading: for diagnosed generalized anxiety disorder and other clinically significant anxiety, SSRIs combined with cognitive-behavioral therapy are the validated first-line. Benzodiazepines are appropriate for short-term acute use only. Selank may have a research-adjunct role in some patient discussions, particularly where benzodiazepine alternatives are sought, but Western controlled trial validation is the missing evidence layer. Anyone framing Selank as a validated benzodiazepine alternative in 2026 is reading further into the Western evidence base than the available data supports.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Of the 6 most-discussed peptides for cognitive enhancement, one (Cerebrolysin) holds approval in over 50 countries for stroke, TBI, and dementia indications. Two (Semax, Selank) are approved in Russia for stroke recovery, cognitive disorders, and generalized anxiety disorder. The other three sit at preclinical evidence depth with strong mechanism rationales. Here is what each one's trials and animal studies actually show.
Cerebrolysin
Deepest international clinical evidence on this page. Approved in 50+ countries for stroke, TBI, vascular dementia, and adjuvant Alzheimer's use. Not US-approved.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Domain | Animal Studies | Human Trials |
|---|---|---|
Ischemic stroke recovery early post-stroke window | 18 Reduced infarct size, improved motor recovery, and enhanced neurogenesis reported across multiple animal stroke models. | 8 Multiple Phase 3 RCTs including CARS and CARS-2 reported functional recovery improvements at 90-day follow-up. Meta-analyses replicated effect direction. Approved in 50+ countries for ischemic stroke. |
Traumatic brain injury moderate-severe TBI | 12 Reduced cerebral edema, improved neurobehavioral recovery, and preserved synaptic markers reported in animal TBI models. | 4 Multiple Phase 3 trials supported approval in TBI indications in several jurisdictions. Effect sizes modest but consistent. |
Alzheimer's disease adjuvant to cholinesterase inhibitors | 8 Reduced amyloid pathology, preserved cholinergic neurons, and improved cognitive performance reported in transgenic AD models. | 6 Phase 3 RCTs reported cognitive benefits on ADAS-cog when added to donepezil. Effect sizes variable across trials. |
Vascular dementia post-stroke and chronic cerebrovascular | 6 Improved cognitive performance and reduced white-matter pathology reported in animal vascular dementia models. | 4 Multiple controlled trials support approval in vascular dementia indications across European and Asian markets. |
Mild cognitive impairment MCI prevention and progression | 4 Improved synaptic markers and cognitive performance in aged animal models. | 2 Limited Phase 2/3 evidence in MCI specifically. Most use is in established dementia or stroke recovery. |
Semax
Russian Medicines Registry approved for ischemic stroke recovery and cognitive disorders. BDNF/NGF expression upregulation. Limited Western trial validation.
| Domain | Animal Studies | Human Trials |
|---|---|---|
Ischemic stroke recovery acute and recovery phase | 14 Reduced infarct size, improved neurological recovery, and BDNF upregulation reported across animal stroke models. | 4 Russian Phase 3 trials support stroke recovery indication. Western controlled trial validation absent. |
Cognitive performance under stress sleep deprivation, complex task load | 8 Preserved learning and memory performance under stress conditions reported in rodent models. | 2 Limited Russian clinical exploratory studies in cognitive performance under load. Western controlled trials absent. |
Optic nerve diseases non-cognitive but registered indication | 4 Neuroprotective effects reported in animal optic nerve injury models. | 2 Russian clinical use registered. Limited Western validation. |
Mild cognitive impairment early cognitive decline | 5 Improved cognitive performance reported in aged rodent and chemically-induced cognitive deficit models. | 1 Russian exploratory data; Western controlled trials absent. |
ADHD-spectrum attention deficits pediatric Russian clinical use | 2 Limited animal model data for attention-specific paradigms. | 1 Russian pediatric clinical use reported. Western controlled trials absent. |
Selank
Russian Medicines Registry approved for generalized anxiety disorder. Positioned as benzodiazepine alternative without sedation or dependence. Limited Western trial validation.
| Domain | Animal Studies | Human Trials |
|---|---|---|
Generalized anxiety disorder anxiolytic efficacy | 12 Anxiolytic effects in elevated plus maze, light-dark box, and other anxiety paradigms reported across multiple rodent strains. | 3 Russian clinical trials report anxiolytic effects comparable to benzodiazepines without sedation or dependence liability. Western controlled trials absent. |
Anxiety-related cognitive impairment attention, working memory under anxiety load | 8 Preserved cognitive performance under anxiogenic conditions reported in rodent models. | 2 Russian clinical evidence reports concurrent anxiety reduction and cognitive performance improvement in GAD populations. |
Adjustment disorder stress-related cognitive function | 4 Stress-buffering effects in rodent stress paradigms. | 1 Russian clinical use as adjunctive therapy in adjustment disorder. Western validation absent. |
Depression-anxiety overlap mood with cognitive component | 4 Antidepressant-like effects in forced swim and tail suspension paradigms. | 0 No published controlled trials specifically for depression indication. |
Dihexa
Strongest preclinical cognitive enhancement signal through HGF mimicry and dendritic spine remodeling. Zero published human trials.
| Domain | Animal Studies | Human Trials |
|---|---|---|
Scopolamine-induced cognitive deficit cholinergic-deficit model | 8 Reversed scopolamine-induced learning impairment with effect sizes substantially larger than donepezil in the same paradigm. | 0 Zero published interventional trials. |
Age-related cognitive decline aged-rodent learning tasks | 6 Improved learning and memory performance in aged rats versus age-matched controls in Morris water maze and radial arm maze paradigms. | 0 Zero published trials in age-related cognitive decline. |
Dendritic spine density structural plasticity | 4 Increased hippocampal dendritic spine density and synaptic markers after subchronic Dihexa administration. | 0 Zero human evidence. |
Alzheimer's disease (preclinical) transgenic AD mouse models | 5 Improved cognitive performance and reduced pathological markers in transgenic AD mouse models. | 0 Zero human trials. |
Traumatic brain injury (preclinical) post-TBI cognitive sequelae | 3 Limited preclinical TBI cognitive recovery data. | 0 Zero human trials. |
PE-22-28
TREK-1 channel inhibitor with faster-onset antidepressant and cognitive resilience effects in animal models. Zero published human trials.
| Domain | Animal Studies | Human Trials |
|---|---|---|
Depression with cognitive impact preclinical antidepressant paradigms | 10 Antidepressant effects in forced swim test, tail suspension test, novelty-suppressed feeding, and chronic mild stress paradigms with faster onset than SSRI references. | 0 Zero published interventional trials. |
Stress-induced cognitive decline cognitive resilience under chronic stress | 6 Preserved cognitive performance under chronic mild stress conditions in rodent models. | 0 Zero published trials. |
TREK-1 channel modulation mechanistic foundation | 8 Selective TREK-1 inhibition demonstrated across electrophysiology and binding studies. | 0 Zero human evidence. |
Anxiety-cognition overlap anxiety with cognitive component | 4 Limited preclinical evidence for anxiety paradigms specifically. | 0 Zero published trials. |
P21 (acidic-Y17)
Eleven-amino-acid NGF mimetic with preclinical Alzheimer's-model data. Reduced amyloid pathology in 3xTg-AD mice. Zero published human trials.
| Domain | Animal Studies | Human Trials |
|---|---|---|
Alzheimer's disease (preclinical) transgenic AD mouse models | 8 Reduced amyloid-beta pathology, restored synaptic markers, preserved cholinergic neurons, and improved cognitive performance reported in 3xTg-AD and related models. | 0 Zero published interventional trials. |
NGF mimetic activity TrkA receptor partial agonism | 6 Selective TrkA receptor partial agonism without full-length NGF side effects (poor pharmacokinetics, pain liability) demonstrated in cell culture and animal models. | 0 Zero human evidence. |
Cognitive aging (general) aged-rodent cognitive function | 4 Improved cognitive performance in aged rodent models. | 0 Zero published trials. |
Cholinergic system preservation basal forebrain cholinergic neurons | 3 Preserved cholinergic neurons in basal forebrain reported in chemically-induced and transgenic models. | 0 Zero human trials. |
What's Marketed vs What's Studied
6 common claims, corrected.
“Cerebrolysin is FDA-approved for cognitive enhancement in the United States.”
Cerebrolysin is approved in over 50 countries for ischemic stroke, traumatic brain injury, vascular dementia, and adjuvant Alzheimer's use. It is NOT US FDA-approved for any indication. US patients seeking Cerebrolysin typically import for personal use under FDA's compassionate-use provisions.
“Semax and Selank are validated by decades of Western clinical trials.”
Semax and Selank are registered in the Russian Medicines Registry with decades of Russian clinical use. Western multicenter controlled trials are absent. Russian clinical literature is real and substantial but not equivalent to Western Phase 3 trial validation.
“Dihexa produces dramatic cognitive enhancement in humans.”
Dihexa shows striking cognitive enhancement effect sizes in animal models, particularly in scopolamine-induced cognitive deficit paradigms. Zero published human trials exist as of 2026. The translation from animal magnitude to validated human cognitive enhancement is the missing evidence layer.
“PE-22-28 is a validated faster-onset antidepressant.”
PE-22-28 shows antidepressant effects in animal models with faster onset than SSRI references in standard paradigms. Zero published human trials exist. The faster-onset claim applies to animal evidence, not to validated human clinical experience.
“P21 (acidic-Y17) prevents Alzheimer's disease in humans.”
P21 reduces amyloid pathology and improves cognitive performance in transgenic mouse models of Alzheimer's disease. Zero published human trials exist. Animal-model improvement does not establish human disease-prevention efficacy.
“Cognitive-enhancement peptides replace cholinesterase inhibitors and anti-amyloid antibodies for diagnosed Alzheimer's disease.”
Cholinesterase inhibitors, memantine, lecanemab, and donanemab are FDA-approved with Phase 3 trial evidence. Cognitive-enhancement peptides do not have equivalent US approval or trial evidence. Substituting peptides for validated dementia treatment risks accelerated cognitive decline.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Get a clear cognitive condition diagnosis first.
Alzheimer's disease, vascular dementia, mild cognitive impairment, ADHD, generalized anxiety disorder, depression with cognitive impact, and post-stroke cognitive recovery are different conditions with different treatment ladders. Neurology, psychiatry, geriatric medicine, or appropriate specialty with formal workup is the right starting point. Self-diagnosis followed by peptide self-treatment is not evidence-based care.
Exhaust FDA-approved options first where applicable.
For Alzheimer's disease, cholinesterase inhibitors and memantine are validated symptomatic treatment, with anti-amyloid antibodies (lecanemab, donanemab) representing disease-modifying therapy. For ADHD, FDA-approved stimulants and non-stimulants have decades of evidence. For generalized anxiety disorder, SSRIs combined with cognitive-behavioral therapy are the validated first-line. Beginning treatment with research peptides instead of these standards is not appropriate.
Optimize validated lifestyle interventions.
Sleep duration of 7 to 9 hours, aerobic exercise of 150 minutes weekly, resistance training, Mediterranean dietary patterns, social engagement, and continued learning carry decades of cohort and trial evidence with cognitive-enhancement effect sizes that peptide research has not yet matched. Optimize these foundations before considering peptide adjuncts.
Work with a specialist who knows both validated treatments and peptide research.
Avoid clinics whose primary business is selling peptides. A qualified neurologist, psychiatrist, geriatrician, or integrative medicine physician can frame peptides accurately as research-grade adjuncts and identify when validated escalation is needed. The right physician prioritizes cognitive disease control through evidence-based therapy first.
Compounded peptides require physician prescription and licensed pharmacy.
503A pharmacies prepare patient-specific compounds; 503B outsourcing facilities prepare office-use stock. Both require active state licensure. Demand third-party HPLC purity testing and certificates of analysis. International sourcing of Cerebrolysin or Russian-origin peptides should be discussed with a physician familiar with import and personal-use regulatory considerations.
Track objective cognitive markers, not just subjective sense of improvement.
Validated cognitive assessment tools include MMSE, MoCA, ADAS-cog, and computerized cognitive batteries (CANTAB, Cambridge Brain Sciences, Cogstate). For ADHD, validated rating scales (ASRS, Conners) and continuous performance tasks track attention objectively. Subjective improvement on peptides without objective marker improvement is not evidence of effect. Compare peptide adjunct effects against validated lifestyle interventions and medications using the same objective measures.
The regulatory landscape for cognitive-enhancement peptides is dynamic. Cerebrolysin remains FDA-unapproved in the US despite over 50 international approvals; the underlying biologic-style manufacturing complexity and competitive Alzheimer's monoclonal-antibody landscape continue to constrain US approval economics. Semax and Selank remain Russian-registered with no Western approval pathway in active progress. The anti-amyloid antibody class has expanded with FDA approvals of lecanemab (2023) and donanemab (2024), reshaping the Alzheimer's competitive landscape and constraining incentives for new peptide entrants. The Outsourcing Facilities Association is actively litigating FDA compounding decisions in the Northern District of Texas, which could shift availability of compounded versions of Dihexa, PE-22-28, P21, and the Russian-origin peptides. ADHD stimulant supply chain disruptions in 2023-2025 generated patient interest in alternative cognitive-performance approaches but has not translated into approval pathways for cognitive-enhancement peptides. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
Are any cognitive-enhancement peptides FDA-approved in the United States?
No. As of 2026, no peptide on this page is FDA-approved in the United States for any cognitive indication including Alzheimer's disease, vascular dementia, post-stroke cognitive recovery, ADHD, generalized anxiety disorder, or healthy-adult cognitive enhancement. Cerebrolysin is approved in over 50 countries (not the US) for ischemic stroke, traumatic brain injury, vascular dementia, and adjuvant Alzheimer's use. Semax and Selank are registered in the Russian Medicines Registry. Dihexa, PE-22-28, and P21 are preclinical-only research compounds. The validated FDA-approved treatments for cognitive disorders are cholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine, anti-amyloid monoclonal antibodies (lecanemab, donanemab), ADHD stimulants for diagnosed ADHD, and SSRIs for anxiety-related cognitive impairment. None of those is a peptide on this page.
What is Cerebrolysin and why is it not available in the United States?
Cerebrolysin is a parenteral complex of low-molecular-weight peptides (under 10 kDa) and free amino acids derived from purified porcine brain proteins. EVER Neuro Pharma in Austria manufactures it. The drug is registered in over 50 countries for ischemic stroke recovery, traumatic brain injury, vascular dementia, and adjunctive Alzheimer's disease use. The mechanism is neurotrophic mimicry, with the peptide complex acting in a manner pharmacologically analogous to endogenous BDNF, NGF, GDNF, and CNTF signaling. The CARS trial and other Phase 3 evidence anchor international approvals. US FDA submission has not occurred at scale. The combination of complex biologic-style manufacturing, the heterogeneity of the peptide preparation (which complicates US FDA characterization for new chemical entities), and competition from emerging anti-amyloid antibodies in the Alzheimer's market constrains US approval economics. US patients seeking Cerebrolysin typically import for personal use under FDA's compassionate-use provisions.
How do Semax and Selank differ?
Semax and Selank are both synthetic heptapeptides developed in Russia, both share the same Pro-Gly-Pro tripeptide stability extension, and both are registered in the Russian Medicines Registry. They target different indications and operate through different primary mechanisms. Semax is based on the 4-7 fragment of adrenocorticotropic hormone (ACTH) and is registered for ischemic stroke recovery and cognitive disorders. The primary mechanism is BDNF and NGF expression upregulation in cortex and hippocampus, plus melanocortin receptor activity. Selank is based on tuftsin (the natural immunomodulatory tetrapeptide derived from the Fc fragment of immunoglobulin G) and is registered for generalized anxiety disorder. The primary mechanism is GABA and serotonin pathway modulation plus BDNF upregulation. In simplified framing: Semax targets cognitive performance and stroke recovery, Selank targets anxiety with cognitive impact. Both are research-only in the United States.
Is Dihexa actually as effective as the animal studies suggest?
Dihexa shows striking cognitive enhancement in animal models. The Wright laboratory's scopolamine-induced cognitive deficit paradigm reports effect sizes substantially larger than reference cognitive enhancers like donepezil. Aged-rat learning tasks show similar effect direction. The mechanism through HGF/c-Met receptor augmentation and dendritic spinogenesis is mechanistically interesting and well-characterized. As of 2026, zero published controlled human trials of synthetic Dihexa exist. The translation from animal model magnitude to validated human cognitive enhancement is the missing evidence layer. Animal-model effect sizes do not always translate proportionally to human outcomes. Pharmacokinetics, dose-response relationships, and long-term safety in humans are uncharacterized. Anyone treating animal-model effect sizes as predictive of validated human effect is reading further into the data than the data supports.
Can peptides reverse Alzheimer's disease or stop cognitive decline?
No peptide on this page has FDA approval for Alzheimer's disease in the United States. The closest validated agents in the cognitive-enhancement peptide category are Cerebrolysin (international approval for adjunctive Alzheimer's use) and P21 (preclinical-only with promising 3xTg-AD mouse model data). Disease-modifying treatments for Alzheimer's now include the anti-amyloid monoclonal antibodies lecanemab (Leqembi, FDA approved 2023) and donanemab (Kisunla, FDA approved 2024), which target amyloid plaque clearance. These represent the first FDA-approved disease-modifying therapies in Alzheimer's disease. Symptomatic treatment includes cholinesterase inhibitors and memantine. None of these is a peptide on this page. Patients with diagnosed Alzheimer's disease should work with neurology and geriatric medicine on validated treatment options. Peptide adjunct discussion may have a research-grade role but should layer alongside, not replace, validated dementia care.
Does Selank work as a benzodiazepine alternative for anxiety?
Russian clinical literature positions Selank as anxiolytic with efficacy comparable to benzodiazepines on validated anxiety scales (Hamilton Anxiety, Spielberger), without the sedation, cognitive impairment, or dependence liability that limits long-term benzodiazepine utility. The mechanism through GABA, serotonin, and BDNF pathway modulation is distinct from benzodiazepine GABA-A potentiation. Russian Phase 3 trials support the Russian Medicines Registry approval for generalized anxiety disorder. Western controlled trials are absent. The Russian evidence base is real but inaccessible to most Western evidence synthesis without specialized translation. PSI's reading: for diagnosed anxiety, validated SSRI and SNRI antidepressants combined with cognitive-behavioral therapy remain the Western evidence-based first-line. Selank may have a research-adjunct role in some patient discussions, particularly where benzodiazepine alternatives are sought. Anyone framing Selank as a validated benzodiazepine alternative in Western practice is reading further into the available evidence than the data supports.
Are these peptides safe to take long-term?
Long-term safety profiles vary by compound. Cerebrolysin has the deepest international safety database from decades of clinical use in 50+ countries. The compound is generally well-tolerated; injection-site reactions, mild headache, vertigo, and rare hypersensitivity reactions are documented. Semax and Selank have decades of Russian clinical use with generally well-tolerated profiles; intranasal administration can produce mild irritation. Western long-term safety data is limited for both. Dihexa, PE-22-28, and P21 lack human safety data of any duration; safety profiles are inferred from animal toxicology only. Compounded peptides are not FDA-regulated products. Purity, potency, and sterility vary by source. Anyone using cognitive-enhancement peptides should do so under physician supervision with awareness that long-term safety profiles, particularly for the preclinical-only compounds, are unknown.
Can I take cognitive-enhancement peptides alongside cholinesterase inhibitors or anti-amyloid antibodies?
Drug-drug interactions for cognitive-enhancement peptides combined with FDA-approved dementia medications are largely uncharacterized in adequately powered human studies. Cerebrolysin is used adjunctively with donepezil in Alzheimer's protocols in countries where it is approved, and Phase 3 trials report concurrent use without major safety concerns. The Alvarez 2011 trial demonstrated additive cognitive benefit of Cerebrolysin plus donepezil over donepezil alone. Other peptide-validated medication combinations have not been systematically studied. Anyone considering cognitive-enhancement peptides while on cholinesterase inhibitors, memantine, or anti-amyloid antibodies should work with neurology that can evaluate the full medication profile. The honest framing: do not substitute peptides for validated dementia medications. Validated medications should not be stopped or compromised by adjunctive peptide use.
What lifestyle interventions have stronger evidence than cognitive-enhancement peptides?
Several lifestyle interventions have far stronger evidence for cognitive enhancement and cognitive decline prevention than any peptide on this page. Sleep duration of 7 to 9 hours nightly correlates with preserved cognitive performance and reduced dementia risk in multiple large cohort studies. Aerobic exercise of 150 minutes weekly improves cognitive performance, increases hippocampal volume on MRI, and reduces dementia incidence. Resistance training adds independent cognitive benefits. Mediterranean dietary patterns (PREDIMED-Plus and similar trials) reduce cognitive decline rates. Social engagement and continued learning carry effect sizes comparable to pharmacological intervention in observational studies. Smoking cessation, blood pressure control, and treatment of hearing loss are validated dementia-risk modifiers per the Lancet Commission on Dementia Prevention. Anyone considering cognitive-enhancement peptides for healthy-adult performance or dementia prevention should optimize these validated interventions first. Peptide adjunct use, where considered, layers alongside validated lifestyle and medical interventions, not as a substitute.
How long does it take cognitive-enhancement peptides to show effects?
Animal studies of cognitive-enhancement peptides report measurable cognitive performance changes within 7 to 28 days. Cerebrolysin clinical trials in stroke recovery use 10 to 30 day intravenous infusion cycles and measure functional recovery at 90-day follow-up. Russian clinical trials of Semax and Selank typically use 14 to 21 day intranasal courses with measurement at 30 to 90 days. For comparison, validated treatments have well-characterized timelines. Cholinesterase inhibitors typically show cognitive benefit within 12 weeks. Anti-amyloid antibodies (lecanemab, donanemab) measure efficacy on disease-progression endpoints over 18 months. ADHD stimulants produce immediate effect within hours. SSRIs typically show anxiolytic and cognitive bandwidth restoration over 2 to 6 weeks. Anyone evaluating cognitive-enhancement peptides should expect a minimum 4 to 12 week timeline. Do not abandon validated treatment to test peptides.
Are cognitive-enhancement peptides legal in the United States?
Regulatory status varies by compound. None of the peptides on this page is FDA-approved in the United States for any cognitive indication. Cerebrolysin can be imported for personal use under FDA's compassionate-use provisions. Compounded versions of Semax, Selank, Dihexa, PE-22-28, and P21 are available through some 503A pharmacies with physician prescription, with availability varying by jurisdiction. Research-chemical sourcing exists for all compounds but does not constitute legal medical use. The Outsourcing Facilities Association is actively litigating FDA compounding decisions in the Northern District of Texas, which could shift availability. None of the peptides on this page is WADA-prohibited. Regulatory status is dynamic and varies by country.
How does cognitive-enhancement peptide research compare to anti-amyloid antibodies for Alzheimer's?
Anti-amyloid monoclonal antibodies represent a paradigm shift in Alzheimer's disease treatment. Lecanemab (Leqembi) received FDA accelerated approval in 2023 and traditional approval based on Phase 3 CLARITY-AD trial showing slowed cognitive decline. Donanemab (Kisunla) followed with FDA approval in 2024 based on TRAILBLAZER-ALZ 2 trial data. These agents target amyloid plaque clearance and represent the first disease-modifying Alzheimer's therapies. Effect sizes are modest but represent genuine disease modification. Cerebrolysin has international approval for adjunctive Alzheimer's use with neurotrophic mimicry mechanism, but is not US-approved and is not equivalent to anti-amyloid antibody trial evidence. P21 has preclinical Alzheimer's-model data through NGF mimicry, with zero human trials. Anti-amyloid antibodies are FDA-approved with Phase 3 evidence. Cognitive-enhancement peptides remain research-grade or internationally-approved-only options. The two categories should not be presented as equivalent.
What are the side effects of cognitive-enhancement peptides?
Side-effect profiles vary by compound. Cerebrolysin is generally well-tolerated based on the international clinical safety database; common effects include injection-site reactions, mild headache, vertigo, and rare hypersensitivity. Semax and Selank intranasal administration can produce mild nasal irritation; otherwise generally well-tolerated in Russian clinical use. Dihexa, PE-22-28, and P21 lack human safety data; side-effect profiles are inferred from animal toxicology. The compounded peptide channel adds purity and potency variation as a separate concern. Compounded peptides are not FDA-regulated products. Purity, potency, and sterility vary by source. Anyone considering cognitive-enhancement peptides should work with a physician who can evaluate the medication context and monitor for adverse effects.
Should I use peptides for ADHD or attention deficits?
Validated ADHD treatments include FDA-approved stimulants (methylphenidate, amphetamine salts, lisdexamfetamine) and non-stimulant options (atomoxetine, guanfacine, clonidine). These agents have decades of Phase 3 trial evidence in diagnosed ADHD with established benefit on attention, executive function, and academic or workplace performance. Semax has Russian clinical use including in pediatric attention deficit contexts, but Western controlled trials in ADHD specifically are absent. Selank's anxiolytic profile may have indirect cognitive benefit through anxiety reduction, but it is not validated for ADHD. Dihexa, PE-22-28, and P21 are preclinical-only. Patients with diagnosed ADHD should work with psychiatry on validated treatment. Off-label peptide use for attention deficits without ADHD diagnosis raises clinical, ethical, and safety questions that should be discussed with a physician familiar with both ADHD and peptide research.
What questions should I ask a doctor about cognitive-enhancement peptides?
Ask: (1) Is there a specific cognitive condition where peptide research applies to my situation, or am I exploring general cognitive enhancement? Treatment depends on diagnosis. (2) Have I exhausted validated lifestyle interventions (sleep optimization, structured exercise, Mediterranean diet, social engagement) and validated medications where applicable before considering peptides? (3) What evidence level supports the peptide being considered for my specific condition? International approval, Russian clinical use, or preclinical-only animal data. (4) For diagnosed Alzheimer's disease, vascular dementia, ADHD, or generalized anxiety disorder, what FDA-approved treatments have I tried first? (5) What are the long-term safety considerations for the specific compound, and what monitoring is appropriate? (6) Are the compounded formulations being prescribed from a state-licensed compounding pharmacy with third-party analytical testing? (7) How will we measure whether the peptide is working using objective cognitive performance metrics?
Can cognitive-enhancement peptides help with cognitive decline from chronic stress, sleep deprivation, or burnout?
Chronic stress, sleep deprivation, and burnout produce cognitive impairment through validated mechanisms including elevated cortisol, reduced BDNF expression, hippocampal volume loss, and disrupted prefrontal cortex function. The validated interventions are restorative: sleep hygiene, sleep duration of 7 to 9 hours, stress management techniques (mindfulness, cognitive-behavioral therapy, exercise), workload modification, and treatment of underlying mood or anxiety disorders. Peptide research for stress-induced cognitive decline is preliminary. Selank has Russian clinical literature showing concurrent anxiety reduction and cognitive performance improvement. Semax has stress-buffering effects in Russian preclinical and clinical exploratory data. PE-22-28 has stress-resilience effects in animal models. Cerebrolysin is not specifically positioned for stress-induced cognitive decline. The honest framing: addressing chronic stress, sleep deprivation, or burnout requires the underlying lifestyle and mental health work first. Peptide adjunct use, where considered, layers alongside validated stress-management and sleep interventions, not as a substitute.
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.